EP Global Communications, Inc. (OTCMKTS:EPGL) shares were down 0.81% to $0.0490 on Friday. The company has a market cap of $226.88 million at 4.67 billion shares outstanding. Share prices have been trading in a 52-week range of $0.02 to $0.07.

EP Global Communications is  an advanced technology research and development company for both medical devices and consumer electronics devices specializing in microelectronic mechanical systems. It is ocused on developing and marketing medical devices for both diagnosis and treatment of chronic pain and is working to invent and develop additional medical device technology products, including biomedical devices that utilize bio-MEMS.

Among its products are the muscle pain detection device, which  is a clinical and technological platform, which diagnoses the muscle pain and has received 510K clearance from the US Food and Drug Administration for marketing and manufacturing. This product incorporates two technologies, one of clinical methodology and one for device technology, for a combined diagnostic package that allows for muscle pain diagnosis.

In a press release last month, EP Global Communications announced that  it has been notified of an allowance from the United States Patent & Trademark Office on its first patent for “System for Contact Lens Wireless Communication.”

Our methods allow integration of flexible electronics into the contact lens during the manufacturing process without major changes to the current process.  We also have solutions in the areas of autofocus and optics for augmented reality contact lenses,” said David Markus, PhD.

Markus added that they have several patents pending in the field of smart contact lenses and augmented vision technology. These technologies have attracted the attention of major industry players, including Johnson & Johnson which in April acquired the first rights to negotiate purchase of these pending technologies in smart contact lenses. These technologies revolve around the integration of electronics into modern Silicone Hydrogel lenses.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.